Cargando…
RARE-17. HIGH-THROUGHPUT SCREEN IDENTIFIES POTENTIAL CHEMOTHERAPIES FOR CHOROID PLEXUS CARCINOMA TREATMENT USING INTRAARTERIAL STRATEGY
Choroid plexus carcinoma is a rare infantile brain tumor with an aggressive clinical course.(1) There is no optimal treatment and survival is poor. Gross total surgical removal is the single most important predictor of survival.(1) Gross total surgical removal rates are inconsistent and associated w...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168223/ http://dx.doi.org/10.1093/neuonc/noab090.178 |
_version_ | 1783701847108747264 |
---|---|
author | Martin, Brice Thomas, Craig Garman, Tyler Lin, Daisy Dahmane, Nadia Souweidane, Mark |
author_facet | Martin, Brice Thomas, Craig Garman, Tyler Lin, Daisy Dahmane, Nadia Souweidane, Mark |
author_sort | Martin, Brice |
collection | PubMed |
description | Choroid plexus carcinoma is a rare infantile brain tumor with an aggressive clinical course.(1) There is no optimal treatment and survival is poor. Gross total surgical removal is the single most important predictor of survival.(1) Gross total surgical removal rates are inconsistent and associated with significant morbidity owing to the hemorrhagic nature of these tumors compounded by a small circulating blood volume. Neoadjuvant systemic chemotherapy with “second look surgery” helps to achieve gross total surgical removal(2) but has an inefficient pharmacokinetic profile and exposes children to dose- limiting toxic side effects. Hence, there is a strong need to identify and develop new agents and strategies to improve current choroid plexus carcinoma (CPC) treatment. Here, we report a high-throughput drug screening using a CPC cancer tissue-originated from a 7-year-old male patient and procured (Children’s Cancer Hospital Egypt) to identify new potent drugs. The selected candidates have been used as single agent and combination agent chemotherapy to propose a relevant study (e.g pharmacokinetics, toxicity, biodistribution, anticancer efficacy) for improving CPC treatment using a pre-existing intraarterial chemotherapy. A genetically engineered model has been developed by Shannon et al by breeding RosamTmG with Nestin-Cre to generate Nestin-cre/Rosa ( mTmG ) reporter mice overexpressing c-Myc, which provides a fully penetrant model of CPC in the lateral ventricle CP and 4(th) ventricle CP.(3) This mice model will be used to explore in vivo the newly discovered drug combinations to treat the CPC tumor. 1. Hosmann, A. et al. Management of choroid plexus tumors—an institutional experience. Acta Neurochir. (Wien). 161, 745–754 (2019) 2. Schneider, C. et al. Neoadjuvant chemotherapy reduces blood loss during the resection of pediatric choroid plexus carcinomas *christian. J. Neurosurg. Pediatr. Pediatr. 16, 126–133 (2015) 3. Shannon, M. L. et al. Mice Expressing Myc in Neural Precursors Develop Choroid Plexus and Ciliary Body Tumors. Am. J. Pathol. 188, 1334–1344 (2018) |
format | Online Article Text |
id | pubmed-8168223 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-81682232021-06-02 RARE-17. HIGH-THROUGHPUT SCREEN IDENTIFIES POTENTIAL CHEMOTHERAPIES FOR CHOROID PLEXUS CARCINOMA TREATMENT USING INTRAARTERIAL STRATEGY Martin, Brice Thomas, Craig Garman, Tyler Lin, Daisy Dahmane, Nadia Souweidane, Mark Neuro Oncol Rare Tumors/Other Choroid plexus carcinoma is a rare infantile brain tumor with an aggressive clinical course.(1) There is no optimal treatment and survival is poor. Gross total surgical removal is the single most important predictor of survival.(1) Gross total surgical removal rates are inconsistent and associated with significant morbidity owing to the hemorrhagic nature of these tumors compounded by a small circulating blood volume. Neoadjuvant systemic chemotherapy with “second look surgery” helps to achieve gross total surgical removal(2) but has an inefficient pharmacokinetic profile and exposes children to dose- limiting toxic side effects. Hence, there is a strong need to identify and develop new agents and strategies to improve current choroid plexus carcinoma (CPC) treatment. Here, we report a high-throughput drug screening using a CPC cancer tissue-originated from a 7-year-old male patient and procured (Children’s Cancer Hospital Egypt) to identify new potent drugs. The selected candidates have been used as single agent and combination agent chemotherapy to propose a relevant study (e.g pharmacokinetics, toxicity, biodistribution, anticancer efficacy) for improving CPC treatment using a pre-existing intraarterial chemotherapy. A genetically engineered model has been developed by Shannon et al by breeding RosamTmG with Nestin-Cre to generate Nestin-cre/Rosa ( mTmG ) reporter mice overexpressing c-Myc, which provides a fully penetrant model of CPC in the lateral ventricle CP and 4(th) ventricle CP.(3) This mice model will be used to explore in vivo the newly discovered drug combinations to treat the CPC tumor. 1. Hosmann, A. et al. Management of choroid plexus tumors—an institutional experience. Acta Neurochir. (Wien). 161, 745–754 (2019) 2. Schneider, C. et al. Neoadjuvant chemotherapy reduces blood loss during the resection of pediatric choroid plexus carcinomas *christian. J. Neurosurg. Pediatr. Pediatr. 16, 126–133 (2015) 3. Shannon, M. L. et al. Mice Expressing Myc in Neural Precursors Develop Choroid Plexus and Ciliary Body Tumors. Am. J. Pathol. 188, 1334–1344 (2018) Oxford University Press 2021-06-01 /pmc/articles/PMC8168223/ http://dx.doi.org/10.1093/neuonc/noab090.178 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Rare Tumors/Other Martin, Brice Thomas, Craig Garman, Tyler Lin, Daisy Dahmane, Nadia Souweidane, Mark RARE-17. HIGH-THROUGHPUT SCREEN IDENTIFIES POTENTIAL CHEMOTHERAPIES FOR CHOROID PLEXUS CARCINOMA TREATMENT USING INTRAARTERIAL STRATEGY |
title | RARE-17. HIGH-THROUGHPUT SCREEN IDENTIFIES POTENTIAL CHEMOTHERAPIES FOR CHOROID PLEXUS CARCINOMA TREATMENT USING INTRAARTERIAL STRATEGY |
title_full | RARE-17. HIGH-THROUGHPUT SCREEN IDENTIFIES POTENTIAL CHEMOTHERAPIES FOR CHOROID PLEXUS CARCINOMA TREATMENT USING INTRAARTERIAL STRATEGY |
title_fullStr | RARE-17. HIGH-THROUGHPUT SCREEN IDENTIFIES POTENTIAL CHEMOTHERAPIES FOR CHOROID PLEXUS CARCINOMA TREATMENT USING INTRAARTERIAL STRATEGY |
title_full_unstemmed | RARE-17. HIGH-THROUGHPUT SCREEN IDENTIFIES POTENTIAL CHEMOTHERAPIES FOR CHOROID PLEXUS CARCINOMA TREATMENT USING INTRAARTERIAL STRATEGY |
title_short | RARE-17. HIGH-THROUGHPUT SCREEN IDENTIFIES POTENTIAL CHEMOTHERAPIES FOR CHOROID PLEXUS CARCINOMA TREATMENT USING INTRAARTERIAL STRATEGY |
title_sort | rare-17. high-throughput screen identifies potential chemotherapies for choroid plexus carcinoma treatment using intraarterial strategy |
topic | Rare Tumors/Other |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168223/ http://dx.doi.org/10.1093/neuonc/noab090.178 |
work_keys_str_mv | AT martinbrice rare17highthroughputscreenidentifiespotentialchemotherapiesforchoroidplexuscarcinomatreatmentusingintraarterialstrategy AT thomascraig rare17highthroughputscreenidentifiespotentialchemotherapiesforchoroidplexuscarcinomatreatmentusingintraarterialstrategy AT garmantyler rare17highthroughputscreenidentifiespotentialchemotherapiesforchoroidplexuscarcinomatreatmentusingintraarterialstrategy AT lindaisy rare17highthroughputscreenidentifiespotentialchemotherapiesforchoroidplexuscarcinomatreatmentusingintraarterialstrategy AT dahmanenadia rare17highthroughputscreenidentifiespotentialchemotherapiesforchoroidplexuscarcinomatreatmentusingintraarterialstrategy AT souweidanemark rare17highthroughputscreenidentifiespotentialchemotherapiesforchoroidplexuscarcinomatreatmentusingintraarterialstrategy |